tbuckley/cabot-search huggingface dataset:
MicroRNA-411 and Its 5′-IsomiR Have Distinct Targets and Functions and Are Differentially Regulated in the Vasculature under Ischemia
Authors: Reginald V.C.T. van der Kwast, Tamar Woudenberg, Paul H.A. Quax, A. Yaël Nossent
Journal: Molecular Therapy (2019)

MicroRNAs are posttranscriptional regulators of gene expression. As microRNAs can target many genes simultaneously, microRNAs can regulate complex multifactorial processes, including post-ischemic neovascularization, a major recovery pathway in cardiovascular disease. MicroRNAs select their target mRNAs via full complementary binding with their seed sequence, i.e., nucleotides 2–8 from the 5′ end of a microRNA. The exact sequence of a mature microRNA, and thus of its 5′ and 3′ ends, is determined by two sequential cleavage steps of microRNA precursors, Drosha/DGCR8 and Dicer. When these cleavage steps result in nucleotide switches at the 5′ end, forming a so-called 5′-isomiR, this results in a shift in the mature microRNA's seed sequence. The role of 5′-isomiRs in cardiovascular diseases is still unknown. Here, we characterize the expression and function of the 5′-isomiR of miR-411 (ISO-miR-411). ISO-miR-411 is abundantly expressed in human primary vascular cells. ISO-miR-411 has a different "targetome" from WT-miR-411, with only minor overlap. The ISO-miR-411/WT-miR-411 ratio is downregulated under acute ischemia, both in cells and a murine ischemia model, but is upregulated instead in chronically ischemic human blood vessels. ISO-miR-411 negatively influences vascular cell migration, whereas WT-miR-411 does not. Our data demonstrate that isomiR formation is a functional pathway that is actively regulated during ischemia.Graphical abstract
Whole Genome Amplification with Subsequent High Throughput Sequencing Allows Comprehensive Genome-Wide Analysis of Single Leukemic Cells
Authors: Vera Binder, Christoph Bartenhagen, Vera Okpanyi, Bianca Behrens, Birte Moehlendick, Hans-Ulrich Klein, Harald Rieder, Michael Gombert, Martin Dugas, Nikolas Hendrik Stoecklein, Arndt Borkhardt
Journal: Blood (2011)
The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability Of Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients In An Open-Label Extension Study
Authors: Susan O'Brien, Richard R. Furman, Nathan Fowler, Steven E. Coutre, Jeff P. Sharman, Kristie A. Blum, Jan A. Burger, Jeffrey A. Jones, William G. Wierda, Emiliano Mugnaini, Ian Flinn, Ranjana H. Advani, Kathryn S. Kolibaba, Yun Shaw, Fong Clow, Danelle F. James, Alvina D. Chu, John C. Byrd
Journal: Blood (2013)
Interferon Alpha-2B (IFN-a) Is an Effective Agent for the Treatment of Primary Cutaneous T- and B-Cell Lymphoma.
Authors: Marina P. Siakantaris, Marie-Christine Kyrtsonis, Tatiana Tzenou, Evangelia M. Dimitriadou, Maria N. Dimopoulou, Maria K. Angelopoulou, Styliani I. Kokoris, Theodoros P. Vassilakopoulos, Penelope Korkolopoulou, Antonia Giannakakis, Eleni Plata, Eustratios Patsouris, Andreas Katsambas, Gerassimos A. Pangalis
Journal: Blood (2004)
Flow Cytometric Leukemic Blasts Detection in Cerebrospinal Fluid of Children with Acute Lymphoblastic Leukemia
Authors: Mette Levinsen, Hanne Vibeke Marquart, Line Groth-Pedersen, Thomas Leth Frandsen, Birgitte Klug Albertsen, Cornelis J.H. Pronk, Jesper Heldrup, Aina Ulvmoen, Goda Vaitkeviciene, Peder Skov Wehner, Britt-Marie Frost, Jonas Abrahamsson, Arja Harila-Saari, Riitta Niinimäki, Päivi Lähteenmäki, Ann Åsberg, Bendik Lund, Maria Winther Gunnes, Ulrika Norén-Nyström, Mikael Behrendtz, Jouni Pesola, Mervi Taskinen, Kjeld Schmiegelow
Journal: Blood (2014)
Genetic Architecture of Relapsed Pediatric B Cell Precursor Acute Lymphoblastic Leukemia Are Related to the Intensity of Upfront Therapy
Authors: Jiangyan Yu, Esmé Waanders, Simon V. van Reijmersdal, Edwin Sonneveld, Frank N. van Leeuwen, Rob Pieters, Ad Geurts van Kessel, Peter M. Hoogerbrugge, Roland P. Kuiper
Journal: Blood (2015)
Inhibitors of poly(ADP-ribose) glycohydrolase (PARG) exhibit single agent therapeutic activity and sensitize glioblastoma cells to ionizing radiation
Authors: Mark Jackson, Natividad Gomez-Roman, Anthony Chalmers
Journal: Neuro-Oncology (2019)

Abstract Objective The lack of an effective therapy for glioblastoma (GBM) largely results from the intrinsic resistance of GBM cells. The radiosensitizing activity of inhibitors of poly(ADP-ribose) polymerases (PARPs) highlights the important role of poly(ADP-ribose) (PAR) in the DNA damage response. In contrast to PARPs, inhibition of poly(ADP-ribose) glycohydrolase (PARG), the enzyme responsible for degrading PAR chains, has shown single agent therapeutic activity in non-glioma cancer cells. This work aims to validate the therapeutic potential of PARG inhibitors (PARGi) in GBM. Results Baseline PAR levels were found to vary between different primary and commercial GBM cells, with PARylation increasing upon exposure of cells to ionizing radiation (IR), as expected. Target engagement of a novel PARGi, PDD00017273, was confirmed by the accumulation of nuclear PAR in treated cells. Inhibitor specificity was demonstrated using an inactive control compound and by combining PARGi with the PARP inhibitor olaparib, which blocked the effect. Single agent treatment with PARGi reduced the clonogenic survival of GBM cells in a concentration-dependent manner. Importantly, PARGi also sensitized GBM cells to IR (sensitizer enhancement ratios, SER, ≥ 1.40) Conclusion In contrast to PARP inhibitors, novel PARGi exhibit single agent activity against a panel of GBM cell lines, and also show robust radiosensitizing activity. PARGi therefore have therapeutic potential in this cancer of unmet need.
The Clinical Relevance of Acute Myeloid Leukemia Stem Cells
Authors: Jonathan M. Gerber, B. Douglas Smith, Brownhilda Ngwang, Hao Zhang, Milada Vala, Laura Morsberger, Steven Galkin, Michael Collector, Brandy Perkins, Mark J. Levis, Constance Griffin, Saul J. Sharkis, Michael J. Borowitz, Judith E. Karp, Richard J. Jones
Journal: Blood (2011)
Defective Engraftment of HSPC from C3aR−/ − Mice Reveals an Underappreciated Role of C3a-C3aR Axis in Stem Cell Homing to Bone Marrow.
Authors: Ryan Reca, Magda Kucia, Jarek Baran, Janina Ratajczak, Mariusz Z. Ratajczak
Journal: Blood (2005)
Graft-versus-Tumor Effects after Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning.
Authors: Frederic Baron, Michael B. Maris, Brenda M. Sandmaier, Barry E. Storer, Mohamed Sorror, Razvan Diaconescu, Ann E. Woolfrey, Thomas Chauncey, Marry E.D. Flowers, Marco Mielcarek, David G. Maloney, Rainer Storb
Journal: Blood (2004)
Nonclinical Assessment of Bax 604 (FEIBA STAR) - Reduced Volume Reconstitution &amp; Higher Infusion Rate
Authors: Gerald Hoebarth, Alexandra Kopic, Martin Wolfsegger, Alexander Bauer, Peter L. Turecek, Peter Leidenmuehler, Karima Benamara, Werner Hoellriegl, Marietta Turecek
Journal: Blood (2016)
HDAC Inhibitors Reciprocally Interacts the Wee1 Inhibitor AZD1775 to Abrogate Both the G1/S and G2/M Checkpoints Via Chk1-Related cdc2/Cdk1 Threonine 14 Dephosphorylation in AML Cells
Authors: Yun Dai, Liang Zhou, Yu Zhang, Shuang Chen, Maciej Kmieciak, Yun Leng, Lin Hui, Steven Grant
Journal: Blood (2014)
Outcome of Patients with Aplastic Anemia Given First Line Transplantion or Immunosuppression in the Last Decade: A Report from European Group for Blood and Marrow Transplantation (EBMT).
Authors: Anna Locasciulli, Rosi Oneto, Andrea Bacigalupo, Gerard Socié, Elisabeth Korthof, Albert Bekassy, Hubert Schrezenmeier, Jakob Passweg, Monika Fuhrer
Journal: Blood (2006)
A 200 kb Survey of Chromatin in the ANK-1 Locus Demonstrates an Erythroid-Specific Chromatin Hub That Activates the Erythrocyte Ankyrin (ANK-1E) Promoter.
Authors: Ashley N. Owen, Tyra Wolfsberg, Karina Laflamme, Clara Wong, Yelena Maksimova, Laura Elnitski, Patrick G. Gallagher, David M. Bodine
Journal: Blood (2006)
Germline and Somatic Genetic Characterization of Shwachman-Diamond Syndrome
Authors: Kasiani C. Myers, Adam S. Nelson, Brian Sheehan, Maggie Malsch, Gwendolyn Towers, Audrey Anna Bolyard, Joan Moore, Sara Loveless, Leann Mount, Stella M Davies, Siobán B. Keel, Rabi Hanna, Mark D. Fleming, David C. Dale, Akiko Shimamura
Journal: Blood (2016)
Critical Role for Histone Deacetylase 6 (HDAC6) in the Regulation of IL-6, and the JAK/STA3 Signaling Cascade in Macrophages
Authors: Maritza Lienlaf, Patricio Perez-Villarroel, Fengdong Cheng, Hongwei Wang, Danay Marante, Sean Yoder, Woan Karrune V., Tessa Knox, Stephen Lagor, Javier Pinilla-Ibarz, Edward Seto, Eduardo M. Sotomayor, Alejandro Villagra
Journal: Blood (2012)
The impact of UGT1A1 single-hetero regarding the toxicity of fixed dose irinotecan therapy for advanced gastric cancer
Authors: Shintaro Nakano, Satoshi Yuki, Kentaro Sawada, Tetsuhito Murasaki, Yasuyuki Kawamoto, Hhiroshi Nakatsumi, Shinya Kajiura, Takayuki Ando, Kazuaki Harada, Yoshimitsu Kobayashi, Takuto Miyagishima, Kazuteru Hatanaka, Aya Tanimoto, Atsushi Ishiguro, Takuya Honda, Masayoshi Dazai, Takahide Sasaki, Yoshito Komatsu
Journal: Annals of Oncology (2019)
Phase II Study of Bortezomib, Mitoxantrone and Etoposide In Relapsed/ Refractory Acute Leukemias
Authors: Joanne Filicko-O'Hara, Bijoyesh Mookerjee, Onder Alpdogan, Emmanuel C. Besa, Matthew Carabasi, Elena Gitelson, Margaret Kasner, John L. Wagner, Mark Weiss, Neal Flomenberg
Journal: Blood (2010)
Patient-Derived Induced Pluripotent Stem Cells Revealed ADAM8/CD156 As a Novel Marker of TKI-Resistant Chronic Myeloid Leukemia Cells
Authors: Masashi Miyauchi, Shunya Arai, Akira Honda, Sho Yamazaki, Keisuke Kataoka, Akihide Yoshimi, Kazuki Taoka, Keiki Kumano, Mineo Kurokawa
Journal: Blood (2016)
Impact of Chronic Graft-Versus-Host Disease on Long-Term Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia in First Remission
Authors: Jae-Ho Yoon, Sung-Soo Park, Young-Woo Jeon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Seok Lee
Journal: Blood (2016)
Vital signs: obesity among low-income, preschool-aged children--United States, 2008-2011.
Authors: Ashleigh L. May, Liping Pan, Bettylou Sherry, Heidi M. Blanck, Deborah Galuska, Karen Dalenius, Barbara Polhamus, Laura Kettel-Khan, Laurence M. Grummer-Strawn
Journal: MMWR Morbidity and Mortality Weekly Report (2013)
A Novel, Mercaptoketone-Based HDAC Inhibitor, KD5170 Exerts Marked Inhibition of Osteoclast Formation and Anti-Myeloma Activity In Vitro.
Authors: Rentian Feng, Jeffrey H. Hager, Christian A. Hassig, Shawn A. Scranton Phar, Joseph E. Payne, Markus Y. Mapara, David Roodman, Suzanne Lentzsch
Journal: Blood (2006)
Enforced STAT3 and PU.1 Expression Activates Type I Interferon-Producing Cell and Dendritic Cell Differentiation Programs in Megakaryocyte/Erythrocyte Progenitors.
Authors: Nobuyuki Onai, Aya Onai, Roxane Tussiwand, Antonio Lanzavecchia, Markus G Manz
Journal: Blood (2005)
Pain, Symptoms, AEs, and Recovery after Second Unrelated Donor Collection of Marrow/Peripheral Blood Stem Cells Are Similar to Those of the First Donation
Authors: David Stroncek, Bronwen E. Shaw, Brent Logan, Deidre Marie Kiefer, Pintip Chitphakdithai, Galen E. Switzer, Nirali N Shah, John P. Miller, Dennis L. Confer, Michael A Pulsipher
Journal: Blood (2016)
ECT in a depressed patient after craniotomy
Authors: J K Hsiao, D L Evans
Journal: American Journal of Psychiatry (1984)

ECT was successfully administered to a depressed woman who had had a craniotomy and had postoperative seizures. For ECT after craniotomy, the authors recommend postneurosurgical stabilization, continuation of anticonvulsants if a seizure disorder is present, and proper electrode placement.
Pegylated Liposomal Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (CBVD) in the Treatment of Advanced Primary Cutaneous Lymphomas.
Authors: Elisabetta Abruzzese, Massimiliano Postorino, Tullio Faraggiana, Daniela Renzi, Manuela Rizzo, Micol Quaresima, Livio Pupo, Roberta Cannarsa, Alessandra Spagnoli, Sara Vaccarini, Malgorzata Monika Trawinska, Lucia Anemona, Giuseppe Lombardo, Maria Cantonetti
Journal: Blood (2009)
Poor Outcome in Secondary Acute Myeloid Leukemia (AML): A First Report From the Population-Based Swedish Acute Leukemia Registry
Authors: Soren Lehmann, Vladimir Lazarevic, Ann-Sofi Hörstedt, Erik Hulegårdh, Christer Nilsson, Petar Antunovic, Åsa Rangert Derolf, Lars Möllgård, Bertil Uggla, Lovisa Vennström, Anders Wahlin, Martin Hoglund, Dick Stockelberg, Gunnar Juliusson
Journal: Blood (2012)
Loss of Heterozygosity on Chromosome 9p24 Is the Most Frequent Chromosomal Aberration in Polycythemia Vera and Idiopathic Myelofibrosis.
Authors: Robert Kralovics, Francesco Passamonti, Kun Liu, Soon-Siong Teo, Anthony Bench, Andre Tichelli, Mario Lazzarino, Anthony R. Green, Mario Cazzola, Radek C. Skoda
Journal: Blood (2004)
Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center.
Authors: Fabio P.S. Santos, Stefan Faderl, Guillermo Garcia-Manero, Charles A. Koller, Miloslav Beran, Gautam Borthakur, Carlos Bueso-Ramos, Michael Keating, Jorge Cortes, Hagop M. Kantarjian, Farhad Ravandi
Journal: Blood (2008)
Donor Derived Acute Myeloid Leukaemia Following Allogeneic Cord Blood Transplantation: A Potential Role for RUNX1 and Down Syndrome Critical Region (DSCR) Genes.
Authors: Anna Castleton, Anastasios Chanalaris, Julie Howard-Reeves, Diana Brazma, Julie Glanville, Dean Nizetic, Ronjon Chakraverty, Elisabeth Nacheva
Journal: Blood (2009)
Genome-Wide RNA Tomography of the Hematopoietic Stem Cell Niche in Zebrafish Reveals Unexpected Functional Macrophage-Stem Cell Interactions
Authors: Elliott J Hagedorn, Julie R Perlin, Clara Mao, Brian Li, Christopher D'Amato, Raquel Riquelme, Samantha Collins, Karo Holler, Alexander van Oudenaarden, Jan Philipp Junker, Leonard I. Zon
Journal: Blood (2016)
Arginine Therapy Decreases Oxidative Stress and Attenuates Leukocyte Recruitment in Transgenic and Knockout Sickle Mice Resulting in Improved Microvascular Flow and Reduced Vaso-Occlusion.
Authors: Dhananjay K. Kaul, Xiao-du Liu, Trisha Dasgupta, Xioqin Zhang, Stephana Choong, Robert P. Hebbel
Journal: Blood (2005)
Multi-colour lineage tracing to asses intra-tumour heterogeneity in glioblastoma multiforme
Authors: James Innes, Sebastian Brandner, Silvia Marino
Journal: Neuro-Oncology (2019)

Abstract Background Glioblastoma multiforme (GBM) represents nearly 50% of all malignant brain tumours. Molecular and genomic diagnostics are beginning to unravel the variation between individual tumours. However, there is growing evidence that cellular heterogeneity exists within a single malignancy. Singe cell analysis has demonstrated the presence of subpopulations corresponding to distinct expression profiles. Objective and experimental approach characterisation of the intratumor heterogeneity is essential to understand biological behaviour and therapy response. Through combining a genetically labelled mouse model (rosa26-confetti lineage tracing locus) with genetically engineered GBM model we can label distinct cellular lineages. Results For three-dimensional imaging of these fluorescently labelled tumours we have optimised tissue clearing protocols. Fluorescence activated sorting of genetically labelled tumour cells identifies distinct populations within single tumours. With these techniques can now interrogate the spatial organisation of clones across large areas and we can compare distinct tumour lineages. Outlook Currently, we are engineering human glioblastoma cell lines with genetic fluorescent labels for lineage tracing. Several genetically characterised human cell lines are available for which novel therapeutic targets have been identified. We will apply our lineage tracing approach to investigate the clonal effects of these tailored therapeutics.
Functionalised LRP1 targeted carbon nanotubes across the blood-brain barrier in vitro and in vivo after intravenous injection
Authors: Julie Wang, Houmam Kafa, Noelia Rubio, Sukhvinder Bansal, Frederic Festy, Jane Sosabowski, Joan Abbott, Khuloud Al-Jamal
Journal: Neuro-Oncology (2019)

Abstract Despite extensive research in drug development, brain cancer is still lacking an efficacious cure due to the inability to deliver current therapeutics to the brain across the blood-brain barrier (BBB). Chemically functionalized carbon nanotubes (f-CNT) constitute a novel class of nanomaterials with attractive physical, chemical and electronic properties. The key advantage of f-CNTs is the extremely high surface area to size ratio allowing a high degree of chemical functionalization making them invaluable tools for designing drug delivery systems to the brain. One of the most interesting characteristics of f-CNTs is their ability to translocate across plasma membranes and enter the cells either passively by direct translocation across membranes or actively via endocytosis. Herein, we confirmed the ability of f-CNTs to cross the BBB and reach the brain in in vitro using a co-culture model of PBEC and primary rat astrocytes and in vivo after intravenous injection. Thanks to their unique optical properties, the uptake of f-CNT in brain was confirmed using state-of-the-art spectroscopic imaging techniques such as multi-photon luminescence imaging, fluorescence lifetime microscopy and Raman spectroscopy. Conjugation with angiopep-2 (ANG), a small peptide targeting the LRP1 receptor overexpressed in the BBB and glioma cells, further enhanced brain parenchyma accumulation in healthy brains. Higher uptake in glioma than brain parenchyma was also observed in glioma-bearing mice after intravenous administration. The inherent brain accumulation ability of f-CNTs coupled with improved brain-targeting by ANG favours the future clinical applications of f-CNTs-ANG to deliver active therapeutics for brain glioma therapy.
Knowledge and Awareness of Early Detection Methods and Risk Factors towards Breast and Cervical Cancer in Bangladesh
Authors: Md Shariful Islam, Yeasmin Akter, A.K.M. Mohiuddin, Fatematuz Zuhura Evamoni, Mehedi Hasan, Nabila Binte Jafar, Rayhanul Islam, Neamat Ullah, Mithu Howlader, Arpita Singha Roy
Journal: Annals of Oncology (2019)
Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial
Authors: Allison H Scotch, Robyn M. Scherber, Nan Zhang, Heidi E. Kosiorek, Amylou C. Dueck, Holly Geyer, Veena Fauble, Alessandro M. Vannucchi, Ana Kerguelen Fuentes, Christen Lykkegaard Andersen, Elisabeth Ejerblad, Gunnar Birgegard, Peter L. Johansson, Bjorn Andreasson, David M. Ross, Federico Sackmann, Jean-Loup Demory, Constantine S. Tam, Jan J. Michiels, Deepti Radia, Mohan Mahalakshmi, Daniel Jennings, Joanne C Ewing, Frances Wadelin, Robert N Lown, Victoria Drew, John Hudson, Mary Frances McMullin, Wunna Swe, Jonathan O. Cullis, Nigel Sargant, Paul Moreton, Mari Frances Kilner, Catherine Cargo, Mallika Sekhar, Satareh Shekouhi, Ruben A. Mesa
Journal: Blood (2016)
Re: Jack R. Andrews, Thomas Atwell, Grant Schmit, et al. Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2019;76:244–51
Authors: Angela Pecoraro, Francesco Porpiglia, Pierre I. Karakiewicz
Journal: European Urology (2019)
Effects of the Btk Inhibitor Ibrutinib on Monocyte Responses to Antibodies
Authors: Li Ren, Amanda Campbell, Shalini Gautam, Huiqing Fang, Kavin Fatehchand, Andrew Stiff, Payal Mehta, Xiaokui Mo, Xuexun Fang, John C. Byrd, William Carson, Jonathan P. Butchar, Susheela Tridandapani
Journal: Blood (2015)
Awareness about Cervical Cancer and Its Prevention among the Female Respondents of General Hospital in Bangladesh
Authors: Nur-E- Alam, Mst Mahmuda Khatun, Tarek Molla, Hedayet Ullah, Sumaiya Akter, Humaira Nur Ifa, Salma Akter, Siratul Kubra Shifat, Fabia Rayyan, Rayhan Ali, Tapon Chandra Sen, Farzana Sultana, A.K.M. Nazrul Islam, Shariful Islam, Rehana Pervin, A.K.M Mohiuddin
Journal: Annals of Oncology (2019)
Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis
Authors: Vikas Gupta, Claire N. Harrison, Hans Hasselbalch, Lisa Pieri, Steffen Koschmieder, Francisco Cervantes, Weichao Bao, Stacey Kalambakas, Edric Atienza, Prashanth Gopalakrishna, Florian H. Heidel
Journal: Blood (2015)
Stathmin 1 Is Involved In The Highly Proliferative Phenotype Of High-Risk Myelodysplastic Syndromes and Acute Leukemia Cells
Authors: João Agostinho Machado-Neto, Paula de Melo Campos, Patricia Favaro, Mariana Lazarini, Irene Lorand-Metze, Fernando Ferreira Costa, Sara Teresinha Olalla Saad, Fabiola Traina
Journal: Blood (2013)
Response to Comment on Rubino et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care 2016;39:861–877
Authors: David E. Cummings, Francesco Rubino
Journal: Diabetes Care (2016)

On behalf of the 48 coauthors from our article reporting the findings and recommendations of the 2nd Diabetes Surgery Summit (DSS-II) (1), we sincerely thank Aberle and Goke (2) for their insightful comments about the consideration of sodium–glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes (T2D) shortly after bariatric/metabolic surgery.

The DSS-II was a consensus development conference, culminating a year-long effort to generate new guidelines for the use of “bariatric” operations to expressly treat T2D (i.e., “metabolic surgery”), including among patients not obese enough to qualify for surgery according to traditional BMI-based criteria. Among our 32 position statements, which all had a high consensus rate, one recommendation endorsed the usage …
BCR-ABL Assay Sensitivity of MR4.5 Achieved in &gt;90%, and MR5 in &gt;75% of Samples, through mRNA Selection before qRT-PCR
Authors: David T Yeung, Wendy Tara Parker, Stuart Phillis, Jasmina Georgievski, Hamish S Scott, Timothy P. Hughes, Susan Branford
Journal: Blood (2015)
Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study
Authors: Hiroshi Sakai, Remi Veillon, Alexis B. Cortot, Enriqueta Felip, Julien Mazieres, Masahiro Morise, Tomohiro Sakamoto, Takaaki Tokito, Shinji Atagi, Terufumi Kato, Toru Kumagai, Hiroshi Tanaka, Rolf Bruns, Josef Straub, Juergen Scheele, Xiuning Le, Paul K. Paik
Journal: Annals of Oncology (2019)
Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia
Authors: Sara Buhrlage, Ellen Weisberg, Nathan Schauer, Jing Yang, Ilaria Lamberto, Laura Doherty, Atsushi Nonami, Amanda L. Christie, David M. Weinstock, Richard M. Stone, Nathanael Gray, James D Griffin
Journal: Blood (2016)
Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02 Demonstrate Increased Proliferation and Are Sensitized To Chemotherapeutic Agents
Authors: Monica L. Guzman, Wen Xie, Jeanne P. De Leon, Francis Burrows, Eric J. Feldman, Gail J. Roboz
Journal: Blood (2013)
The Presence of HLA DR15 Antigen in Patients with Severe Aplastic Anemia Does Not Impact Engraftment and Survival After HLA-Identical Sibling Transplantation.
Authors: Minoo Battiwalla, Tao Wang, Jeanette Carreras, H. Joachim Deeg, Mouhab F. Ayas, Rajinder P.S. Bajwa, Biju George, Vikas Gupta, Ricardo Pasquini, Hubert Schrezenmeier, Kirk R. Schultz, Mary Eapen
Journal: Blood (2009)